Effects of serotonergic agents on isolation-induced aggression

Effect of 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy]-1,3-benzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice

Behavioral effects of 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy]-1,3-be nzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, were evaluated using animal models of anxiety and obsessive compulsive disorder and compared against reference compounds. MKC-242 suppressed foot shock-induced fighting behavior without loss of motor coordination in mice as the reference compounds did. The ED50 values of MKC-242, buspirone, tandospirone and diazepam were 1.7, 42, 80 and 2.0 mg/kg, p.o., respectively. The duration of the suppression of fighting by MKC-242 was longer than those of buspirone and tandospirone and comparable to that of diazepam. Similar results were also obtained with the water-lick conflict test in rats. The plasma concentration of MKC-242 in rats was much higher than the reported value of buspirone during 0.25-6 hr after oral administration. In addition, MKC-242 reduced marble burying behavior without reduction of motor activity. Fluoxetine, tandospirone and diazepam also reduced the behavior at non-sedative doses. These findings indicate that MKC-242 possesses a longer-lasting anxiolytic effect than azapirones. This might be due to the high concentration of the compound in plasma. In addition, it is also suggested that MKC-242 possesses an antiobsessional effect.

alpha-Melanocyte-stimulating hormone (alpha-MSH) and melanin-concentrating hormone (MCH) modify monoaminergic levels in the preoptic area of the rat

The effect of perfusion of melanin-concentrating hormone (MCH) or alpha-melanocyte-stimulating hormone (alpha-MSH) (100 ng/microliter) in the ventromedial nucleus (VMN) or medial preoptic area (MPOA) on monoaminergic levels of female rats was measured using microdialysis and HPLC-electrochemical detection. In the MPOA, alpha-MSH raised 5-HIAA concentration, whereas MCH reduced both 5-HT and 5-HIAA. Neither peptide had any effect in the VMN. The opposite effects of the peptides on the serotonergic system might be responsible for their antagonistic or opposite actions previously reported on several CNS functions. Dopamine may mediate the similar effects of the two peptides, because alpha-MSH inhibits dopaminergic release in the MPOA (but not VMN) and MCH tends to follow the same pattern.

Faulty cortisol/serotonin interplay. Psychopathological and biological characterisation of a new, hypothetical depression subtype (SeCA depression)

The hypothesis is proposed of a new subtype of depression named: stressor-precipitated, cortisol-induced, serotonin-related, anxiety/aggression-driven depression (SeCA depression). Biologically, these patients are characterized by impaired 5-HT synthesis and reduced 5-HT1A receptor sensitivity. Under normal conditions these functions proceed marginally; in times of stress they easily fail, due to sustained overproduction of cortisol. Psychopathologically this depression type shows the following characteristics: anxiety and aggression, not mood lowering, heralding a depressive episode; the personality structure shows 'character neurotic' impairments and tolerance for (certain) traumatic life events is low. As specific therapeutic agents selective 5-HT1A agonists and cortisol or CRH antagonists are proposed. Prophylactically, maintenance treatment with 5-HT1A agonists seems indicated as well as psychological interventions to increase the stressor threshold.

Behavioral changes in Anolis carolinensis following injection with fluoxetine

Eight adult male lizards of the genus and species Anolis carolinensis were used in this experiment. In order to induce aggressive responding, animals were caged separately and daily underwent pairing with another male, during which aggressive responses and changes in skin color were measured. After obtaining a baseline measure of aggressive responding, animals were injected either with fluoxetine or vehicle-controls in a cross-over design. Subjects were then exposed to five more days of (non drug) pairing with the intruder male, after which they underwent a second trial with fluoxetine/vehicle. Finally, two post-drug paired-trials were obtained. Fluoxetine injection significantly reduced the aggressive responding in the males while causing the postorbital eyespot to significantly darken. Subjects also showed increased aggressivity and skin-color reactivity subsequent to the two drug trials, although it is unclear if the fluoxetine, or non-specific factors of the injection paradigm, accounted for these changes. These results suggest that serotonergic CNS systems tonically regulate aggression in Anolis carolinesis, similar to that seen in many other species. They further suggest that eyespot-darkening and aggressive responding can be pharmacologically dissociated, implicating serotonin in the regulation of this phenomenon.

Neonatal organizational effects of the 5-HT2 and 5-HT1A subsystems on adult behavior in the rat

Males, females, neonatally androgenized females, and neonatally castrated males were treated over the second week of life with 0.25 mg/kg of either the 5-HT2 agonist 1-(2,5-dimethoxy-3-iodophenyl)-2-aminopropane HCl (DOI), the 5-HT2 antagonist ritanserin (Rit), the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), or the 5-HT1A antagonist WAY100135 (WAY). Exploration, anxiety, sociosexual preferences, and sexual behavior were measured in adulthood. Agents acting on 5-HT1A receptors do not appear to affect organization of any of the behavioral systems studied. DOI increased exploratory activity but in females only, which suggests that testosterone antagonizes the stimulatory effect of 5-HT2 activity on exploration. Neonatal ritanserin selectively reduced anxiety in females, and DOI had a similar effect in androgenized females. This indicates that neonatal 5-HT2 activity is anxiogenic in normal females, anxiolytic in androgenized females, and has no effect on anxiety in males. Males and androgenized females both showed a preference for the female teaser that was abolished by the 5-HT2 agonist, DOI. These results point out that 5-HT2 activity selectively suppresses heterosexual preference induced in the presence of neonatal testosterone. DOI also reduced both male sexual behavior in males and female sexual behavior in androgenized females. Thus, the 5-HT2 system antagonizes the action of testosterone in stimulating heterosexual orientation and sexual activity, and this is independent of genetic sex.

Decreases in aggression in tryptophan-supplemented broiler breeder males are not due to increases in blood niacin levels

In previous studies with feed-restricted broiler breeders, it was found that supplementation with dietary Trp decreases aggressive activity more in socially dominant males than in socially subordinate males. Although it is probable that this effect is mediated centrally by serotonin, an alternative possibility is that it is associated with other metabolic products of Trp such as niacin. The objectives of this study were to determine whether 1) supplemental dietary niacinamide decreases aggression in broiler breeder males, 2) elevated blood niacin levels are associated with a decrease in aggression, and 3) social status influences any of these effects on behavior. Using a randomized complete block design, a control (0.19% Trp, 22 mg niacin/kg), Trp (1.5% Trp, 22 mg niacin/kg), or niacinamide (0.19% Trp, supplemented with 140 mg niacinamide/kg) diet was assigned to each pen. There were 16 birds per pen and three pens per treatment. Birds were maintained on skip-a-day feed restriction throughout, and behavioral observations were conducted until the social hierarchy in each pen was determined. Treatment diets were then fed from 15 through 18 wk of age, and the number of aggressive pecks and threats per pen recorded in three 20-min observation periods/wk. Blood samples were collected from dominant and subordinate birds and assayed for niacin using Tetrahymena pyriformis. Supplementing the diet with Trp significantly (P < 0.05) decreased aggression. Niacinamide-treated birds did not differ from either Trp-treated or control-treated birds, and no decreases in aggression were seen in birds with elevated blood niacin levels. Blood levels of niacin were, however, higher in dominant niacin-treated birds than in dominant control birds (P < 0.05), although there were no differences among subordinate or Trp-treated birds. Thus, the modulatory effect of Trp on aggression does not appear to be mediated by increased niacin synthesis.

Pharmacotherapy of aggressive behavior

OBJECTIVE

To review the definition, clinical characteristics, prevalence, etiology, neurochemistry, and pharmacologic treatment of aggressive behavior, and provide recommendations regarding the use of specific pharmacologic agents for treating aggressive behavior.

DATA SOURCES

Data from the scientific literature were analyzed, interpreted, and summarized. An English-language MEDLINE search yielded clinical trials, case reports, letters, and review articles addressing the etiology and pharmacotherapy of aggression.

STUDY SELECTION

Because few well-controlled studies are available in aggression research, all literature addressing the pharmacologic treatment of aggressive behavior, as well as the neurochemistry and psychobiology of aggressive behavior, was reviewed.

DATA EXTRACTION

The literature was reviewed on the basis of the particular pharmacotherapy and the specific population used. A separate review of the treatment of aggressive behavior in the elderly was included.

DATA SYNTHESIS

The literature was assessed for applicability to clinical practice and usefulness to the general clinician. Recommendations were made from the primary literature in conjunction with trends in clinical practice. Pharmacotherapy is a primary mainstay of treatment for aggressive patients. In individuals for whom behavioral intervention alone is unsuccessful, drug therapy should be initiated along with continued nonpharmacologic intervention. Short-acting benzodiazepines and high-potency antipsychotic agents are effective in treating acute aggression on a short-term or as needed basis. Agents such as lithium, beta adrenergic blockers, carbamazepine, valproic acid, buspirone, trazodone, serotonin reuptake inhibitors, and clozapine may be useful in the chronic management of aggressive behavior. Every attempt should be made to streamline drug therapy in patients with chronic aggression and comorbid psychiatric disorders.

CONCLUSIONS

On the basis of available research and extensive clinical experience, lithium or propranolol should be considered as first-line antiaggressive agents in patients without comorbid psychiatric disorders. A minimum trial period for assessing drug efficacy should last at least 6-8 weeks at maximum tolerated dosages. Patients responding to pharmacotherapy should be reevaluated every 3-6 months, and periodic medication tapers and/or drug-free periods should be attempted.

Effects of selective serotonergic agonists on aggressive behavior in rats

The effects of the relatively specific serotonergic agonists 8-OH-DPAT (5-HT1A), TFMPP (5-HT1B), and DOB (5-HT2) were studied on defensive aggressive behavior in rats using the water competition test, 8-OH-DPAT (up to 0.25 mg/kg) and TFMPP (up to 1 mg/kg) were found to be ineffective, whereas DOB (up to 0.4 mg/kg) significantly reduced aggressive behavior in this test as well as in the offensive aggression test of the resident-intruder model. These results, combined with those from other studies, suggest that stimulation of 5-HT1A, 5-HT1B, and 5-HT2 receptors reduces offensive aggression, whereas defensive aggression is only decreased by 5-HT2 stimulation.

5-Hydroxytryptamine pathways in anxiety and its treatment

The effects of manipulating 5-hydroxytryptamine (5HT) neuronal function in humans and in animals are reviewed. 5HT pathways do not have a unitary function in modulating anxiety. It is proposed that, rather than acting as input or output channels for brain aversive systems, these pathways provide information concerning waking/motor status, which is crucial to the organisation of appropriate responses to threat. Each terminal region can make use of this information in different ways. Globally, the influence of 5HT neurones on higher centres appears predominantly to facilitate information processing relevant to threat, while their major influence on brainstem centres may be a restraining one.

Serotonergic control of androgen-induced dominance

The present study investigates the role of serotonergic systems in anabolic steroid-induced aggression. An animal model of aggressive dominance was used to assess the chronic effects of testosterone propionate. When rats that had become dominant following administration of testosterone propionate received serotonergic agonists with selectivity for the 5-HT1A receptor (8-OH-DPAT, buspirone, gepirone), the 5-H1B receptor (eltoprazine, TFMPP), or the 5-HT2A/2C receptor (DOM), a dose-dependent decrease in dominance was demonstrated. Pretreatment with three serotonergic antagonists (pizotyline, pirenpirone, and pindolol) blocked agonist-induced reductions in dominance in varying degrees. Nonserotonergic agonists with CNS depressant effects were also tested in dominant animals. The benzodiazepine, chlordiazepoxide, did not reduce dominance except at doses that interfered with motor behavior. The opioid agonist, morphine, dose dependently decreased dominance, but this effect was reversible with administration of the serotonergic antagonist, pirenpirone, suggesting the antidominant effect of morphine had a serotonergic component. Biochemical experiments demonstrated that following chronic testosterone propionate, there was a decrease in levels of 5-HT and 5-HIAA in the hippocampus but not in the striatum or the frontal cortex. Chronic testosterone propionate also caused an increase in the affinity of [3H]8-OH-DPAT for the 5-HT1A receptor but no corresponding change in the density of 5-HT1A binding sites in the hippocampus. There was also no change in the properties of the 5-HT2 receptor in the frontal cortex following chronic testosterone propionate. These data suggest that serotonergic systems may play an important role in the control of anabolic steroid-induced aggressive dominance.

Biphasic effects of typical antidepressants and mianserin, an atypical antidepressant, on aggressive behavior in socially isolated mice

Effects of several typical antidepressants and of an atypical antidepressant, mianserin, on the aggressive behavior (AGB) in long-term isolated mice were examined. IP administration of maprotiline (2.5 and 5 mg/kg), amitriptyline (5 and 10 mg/kg), clomipramine (2.5 and 5 mg/kg), and mianserin (5 mg/kg) significantly increased the duration of AGB. However, at higher doses (maprotiline, 10 mg/kg; amitriptyline, 20 mg/kg; clomipramine, 10 and 20 mg/kg; mianserin, 10 and 20 mg/kg) these antidepressants either did not affect AGB or inhibited it. Amitriptyline (20 mg/kg) and mianserin (10 mg/kg) but not maprotiline (10 mg/kg) or clomipramine (20 mg/kg) decreased spontaneous motor activity in isolated mice. Yohimbine (0.5 mg/kg, IP), an alpha 2-antagonist, changed the antidepressant-induced enhancement of AGB into inhibition without affecting the basal aggressive responses. Prazosin (0.3 mg/kg, IP), an alpha 1-antagonist, did not affect either maprotiline- or clomipramine-induced enhancement of AGB, but it changed the mianserin-induced enhancement of AGB into inhibition. These results indicate that antidepressants that inhibit noradrenaline uptake and/or stimulate noradrenaline output from nerve terminals have biphasic effects on AGB in isolated mice and that the antidepressant-induced enhancement of AGB is mediated by noradrenergic stimulation of alpha 2-adrenoceptors, whereas the antidepressant-induced inhibition of AGB may be mediated by non-alpha 2-adrenoceptors or by nonadrenergic system(s).

5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action?

1. Preclinical and clinical studies suggest that 5-HT1A receptor agonists are a new class of mixed anxiolytics/antidepressants with, possibly, impulsivity reducing properties. 2. The anxiolytic effects of 5-HT1A receptor agonists result predominantly from an interaction with presynaptic 5-HT1A receptors (resulting in a decrease of serotonergic transmission), whereas the antidepressive and, possibly, the impulse control enhancing effects, result predominantly from an interaction with postsynaptic 5-HT1A receptors. 3. These proposed mechanism(s) of action fit well with the generally held view that anxiety is the result of a hypersensitive 5-HT system; whereas impulsivity and depression is the result of a hyposensitive 5-HT system. 4. However, it appears very likely that activation of pre- and postsynaptic 5-HT1A receptors is additionally involved in the antidepressive and impulse control enhancing effects, on the one hand, and in the anxiolytic effects of these compounds, on the other hand. 5. These latter, seemingly paradoxical, findings can be explained by assuming that (1) the presynaptic mechanism reflects an anxiolytic component in the animal models of impulsivity and depression, (2) antagonism of postsynaptic 5-HT1A receptors by these compounds contributes to their anxiolytic effects, (3) postsynaptic 5-HT1A and 5-HT2 receptors have functionally opposing effects or, alternatively, that (4) downregulation of postsynaptic 5-HT2 receptors contributes to the therapeutic effects of these compounds.